Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroblastoma | 57 | 2023 | 1226 | 12.420 |
Why?
|
3-Iodobenzylguanidine | 32 | 2023 | 115 | 7.350 |
Why?
|
Bone Neoplasms | 44 | 2023 | 2529 | 6.580 |
Why?
|
Gene Amplification | 8 | 2022 | 1063 | 2.260 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 36 | 2023 | 11524 | 2.240 |
Why?
|
Neoplasms | 48 | 2023 | 21683 | 2.040 |
Why?
|
Neoplasm Recurrence, Local | 33 | 2023 | 9239 | 1.920 |
Why?
|
Antineoplastic Agents | 36 | 2023 | 13695 | 1.870 |
Why?
|
Osteosarcoma | 12 | 2023 | 881 | 1.810 |
Why?
|
Radiopharmaceuticals | 19 | 2023 | 2645 | 1.780 |
Why?
|
Neoplasms, Second Primary | 10 | 2022 | 1061 | 1.730 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 4 | 2023 | 45 | 1.640 |
Why?
|
Adrenal Gland Neoplasms | 7 | 2022 | 740 | 1.620 |
Why?
|
Child | 147 | 2023 | 77709 | 1.590 |
Why?
|
Iodine Radioisotopes | 11 | 2021 | 1032 | 1.490 |
Why?
|
Vincristine | 12 | 2023 | 1039 | 1.480 |
Why?
|
Radiation-Sensitizing Agents | 6 | 2022 | 358 | 1.450 |
Why?
|
Child, Preschool | 93 | 2023 | 41006 | 1.430 |
Why?
|
Bone Marrow Neoplasms | 2 | 2020 | 104 | 1.360 |
Why?
|
Medical Oncology | 16 | 2023 | 2265 | 1.330 |
Why?
|
Salvage Therapy | 7 | 2021 | 1275 | 1.150 |
Why?
|
Infant | 68 | 2022 | 35136 | 1.150 |
Why?
|
Pyrimidines | 9 | 2022 | 2942 | 1.110 |
Why?
|
Adolescent | 106 | 2023 | 85781 | 1.080 |
Why?
|
Sarcoma | 10 | 2023 | 1897 | 1.070 |
Why?
|
Receptor, trkA | 4 | 2020 | 164 | 1.020 |
Why?
|
Norepinephrine Plasma Membrane Transport Proteins | 4 | 2023 | 66 | 0.990 |
Why?
|
Prognosis | 41 | 2023 | 29063 | 0.920 |
Why?
|
Drug Resistance, Neoplasm | 11 | 2021 | 5172 | 0.920 |
Why?
|
Camptothecin | 3 | 2016 | 576 | 0.910 |
Why?
|
Paraganglioma | 2 | 2022 | 143 | 0.910 |
Why?
|
SEER Program | 13 | 2020 | 1508 | 0.900 |
Why?
|
Soft Tissue Neoplasms | 5 | 2023 | 1363 | 0.890 |
Why?
|
Clinical Trials, Phase I as Topic | 4 | 2023 | 323 | 0.860 |
Why?
|
Central Nervous System Neoplasms | 4 | 2021 | 895 | 0.840 |
Why?
|
Glomus Tumor | 1 | 2022 | 66 | 0.810 |
Why?
|
Indenes | 1 | 2021 | 57 | 0.780 |
Why?
|
Clinical Trials as Topic | 11 | 2021 | 7913 | 0.770 |
Why?
|
Humans | 200 | 2023 | 744343 | 0.770 |
Why?
|
Vesicular Monoamine Transport Proteins | 2 | 2023 | 32 | 0.770 |
Why?
|
Maximum Tolerated Dose | 9 | 2021 | 892 | 0.760 |
Why?
|
Pathology, Molecular | 2 | 2021 | 326 | 0.760 |
Why?
|
Polycythemia | 1 | 2021 | 126 | 0.760 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2020 | 629 | 0.740 |
Why?
|
Minors | 1 | 2020 | 50 | 0.740 |
Why?
|
Young Adult | 59 | 2023 | 56430 | 0.720 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 104 | 0.700 |
Why?
|
Calmodulin-Binding Proteins | 2 | 2011 | 249 | 0.700 |
Why?
|
Gene Fusion | 2 | 2019 | 371 | 0.690 |
Why?
|
Off-Label Use | 1 | 2020 | 169 | 0.660 |
Why?
|
Age Factors | 16 | 2020 | 18370 | 0.640 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2022 | 584 | 0.640 |
Why?
|
Disease-Free Survival | 14 | 2023 | 6895 | 0.640 |
Why?
|
Oncogene Proteins, Fusion | 10 | 2023 | 1581 | 0.630 |
Why?
|
Radionuclide Imaging | 5 | 2022 | 2031 | 0.620 |
Why?
|
Industry | 1 | 2020 | 365 | 0.620 |
Why?
|
Pelvic Neoplasms | 2 | 2022 | 254 | 0.610 |
Why?
|
Azepines | 2 | 2018 | 336 | 0.600 |
Why?
|
Kaplan-Meier Estimate | 14 | 2018 | 6538 | 0.600 |
Why?
|
Ganglioneuroma | 1 | 2017 | 57 | 0.600 |
Why?
|
Pyrazoles | 5 | 2022 | 1972 | 0.580 |
Why?
|
Male | 104 | 2023 | 350118 | 0.570 |
Why?
|
Hydroxamic Acids | 3 | 2015 | 494 | 0.570 |
Why?
|
Oncogene Proteins | 4 | 2015 | 749 | 0.560 |
Why?
|
Thoracic Neoplasms | 2 | 2019 | 268 | 0.560 |
Why?
|
Pyrroles | 4 | 2021 | 1146 | 0.560 |
Why?
|
Etoposide | 7 | 2023 | 641 | 0.560 |
Why?
|
Benzazepines | 1 | 2018 | 326 | 0.560 |
Why?
|
Research Support as Topic | 2 | 2020 | 705 | 0.560 |
Why?
|
Ifosfamide | 6 | 2023 | 228 | 0.540 |
Why?
|
Neoplasm Staging | 15 | 2022 | 11031 | 0.540 |
Why?
|
Wilms Tumor | 3 | 2015 | 373 | 0.530 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1114 | 0.530 |
Why?
|
Survival Rate | 15 | 2021 | 12788 | 0.530 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 332 | 0.520 |
Why?
|
Female | 104 | 2022 | 380194 | 0.520 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2019 | 547 | 0.510 |
Why?
|
Molecular Targeted Therapy | 10 | 2022 | 2727 | 0.500 |
Why?
|
Bone Marrow | 5 | 2020 | 2948 | 0.500 |
Why?
|
Indoles | 4 | 2021 | 1839 | 0.490 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2242 | 0.490 |
Why?
|
Radiotherapy | 3 | 2019 | 1533 | 0.480 |
Why?
|
Infant, Newborn | 23 | 2022 | 25625 | 0.470 |
Why?
|
Adult | 66 | 2023 | 214055 | 0.470 |
Why?
|
Protein Kinase Inhibitors | 10 | 2023 | 5535 | 0.460 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2011 | 934 | 0.450 |
Why?
|
Dysostoses | 1 | 2012 | 9 | 0.450 |
Why?
|
Doxorubicin | 8 | 2023 | 2234 | 0.450 |
Why?
|
Dacarbazine | 1 | 2016 | 566 | 0.440 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2017 | 604 | 0.440 |
Why?
|
Gene Dosage | 1 | 2017 | 1252 | 0.430 |
Why?
|
Annexin A5 | 1 | 2012 | 103 | 0.420 |
Why?
|
Treatment Outcome | 30 | 2021 | 63114 | 0.420 |
Why?
|
Chromosome Aberrations | 5 | 2022 | 1813 | 0.420 |
Why?
|
Nuclear Proteins | 7 | 2022 | 5853 | 0.420 |
Why?
|
RNA-Binding Proteins | 2 | 2011 | 1903 | 0.410 |
Why?
|
Neoplasm Metastasis | 9 | 2019 | 4851 | 0.410 |
Why?
|
Histones | 3 | 2018 | 2599 | 0.390 |
Why?
|
Follow-Up Studies | 22 | 2021 | 39050 | 0.390 |
Why?
|
Neovascularization, Pathologic | 3 | 2014 | 2635 | 0.370 |
Why?
|
Combined Modality Therapy | 14 | 2022 | 8642 | 0.370 |
Why?
|
Carcinoma | 5 | 2022 | 2375 | 0.370 |
Why?
|
Gastrointestinal Stromal Tumors | 3 | 2021 | 643 | 0.360 |
Why?
|
Retrospective Studies | 36 | 2023 | 77449 | 0.360 |
Why?
|
RNA-Binding Protein EWS | 3 | 2021 | 216 | 0.360 |
Why?
|
Topotecan | 2 | 2021 | 137 | 0.340 |
Why?
|
United States Food and Drug Administration | 7 | 2023 | 1584 | 0.340 |
Why?
|
Cohort Studies | 18 | 2020 | 40561 | 0.340 |
Why?
|
Mortality | 1 | 2020 | 2864 | 0.330 |
Why?
|
Proportional Hazards Models | 7 | 2017 | 12354 | 0.330 |
Why?
|
Sirolimus | 4 | 2017 | 1564 | 0.330 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2022 | 5442 | 0.330 |
Why?
|
Introns | 1 | 2011 | 991 | 0.320 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2020 | 1519 | 0.310 |
Why?
|
Translocation, Genetic | 3 | 2021 | 1420 | 0.300 |
Why?
|
Biomedical Research | 2 | 2020 | 3309 | 0.300 |
Why?
|
United States | 23 | 2023 | 69872 | 0.300 |
Why?
|
Kidney Neoplasms | 6 | 2017 | 4262 | 0.300 |
Why?
|
Cytarabine | 1 | 2009 | 692 | 0.290 |
Why?
|
Tissue Distribution | 5 | 2021 | 2327 | 0.290 |
Why?
|
Neoplasm Proteins | 2 | 2021 | 3703 | 0.290 |
Why?
|
Loss of Heterozygosity | 3 | 2019 | 684 | 0.290 |
Why?
|
Databases, Factual | 4 | 2018 | 7729 | 0.280 |
Why?
|
Neoadjuvant Therapy | 5 | 2022 | 2728 | 0.280 |
Why?
|
Drug Approval | 4 | 2023 | 742 | 0.280 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 2282 | 0.280 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2008 | 255 | 0.280 |
Why?
|
Fibrosarcoma | 2 | 2018 | 348 | 0.270 |
Why?
|
Drug Administration Schedule | 6 | 2020 | 4933 | 0.270 |
Why?
|
Pheochromocytoma | 2 | 2022 | 337 | 0.260 |
Why?
|
Drug Dosage Calculations | 3 | 2020 | 114 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2020 | 8428 | 0.260 |
Why?
|
Lymphocyte Count | 1 | 2007 | 793 | 0.250 |
Why?
|
Gene Frequency | 1 | 2011 | 3588 | 0.240 |
Why?
|
Ferritins | 2 | 2019 | 590 | 0.240 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2021 | 990 | 0.240 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 2038 | 0.240 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2023 | 10943 | 0.230 |
Why?
|
Logistic Models | 4 | 2022 | 13408 | 0.220 |
Why?
|
Flow Cytometry | 3 | 2011 | 5974 | 0.220 |
Why?
|
Sarcoma, Small Cell | 1 | 2023 | 22 | 0.220 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2023 | 41 | 0.220 |
Why?
|
Adenocarcinoma | 1 | 2020 | 6364 | 0.220 |
Why?
|
Antibodies, Monoclonal | 5 | 2023 | 9274 | 0.220 |
Why?
|
Radiometry | 4 | 2016 | 800 | 0.220 |
Why?
|
Time Factors | 11 | 2020 | 40075 | 0.220 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2022 | 1660 | 0.210 |
Why?
|
Neutropenia | 3 | 2017 | 895 | 0.210 |
Why?
|
Normetanephrine | 1 | 2021 | 26 | 0.210 |
Why?
|
Brain Neoplasms | 7 | 2022 | 8863 | 0.210 |
Why?
|
Glioma | 3 | 2022 | 3401 | 0.200 |
Why?
|
Leukemia, Lymphoid | 1 | 2002 | 315 | 0.200 |
Why?
|
Lymph Nodes | 1 | 2013 | 3474 | 0.200 |
Why?
|
Granuloma, Plasma Cell | 1 | 2022 | 84 | 0.200 |
Why?
|
Whole-Body Irradiation | 3 | 2016 | 449 | 0.200 |
Why?
|
Proteins | 3 | 2021 | 6103 | 0.200 |
Why?
|
Survival Analysis | 7 | 2020 | 10252 | 0.190 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2021 | 83 | 0.190 |
Why?
|
Registries | 2 | 2020 | 8089 | 0.190 |
Why?
|
Chromogranins | 1 | 2021 | 160 | 0.190 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2018 | 789 | 0.190 |
Why?
|
Genomics | 7 | 2022 | 5720 | 0.190 |
Why?
|
Rhabdomyosarcoma | 2 | 2023 | 382 | 0.190 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2019 | 2948 | 0.190 |
Why?
|
L-Lactate Dehydrogenase | 2 | 2014 | 424 | 0.190 |
Why?
|
Chi-Square Distribution | 2 | 2020 | 3508 | 0.190 |
Why?
|
Drug Monitoring | 2 | 2018 | 956 | 0.190 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2022 | 2455 | 0.190 |
Why?
|
Lymphoma | 2 | 2019 | 1877 | 0.180 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 2734 | 0.180 |
Why?
|
Alleles | 1 | 2011 | 6933 | 0.180 |
Why?
|
Radiotherapy Dosage | 4 | 2020 | 2879 | 0.180 |
Why?
|
Drug Industry | 3 | 2021 | 746 | 0.180 |
Why?
|
Cell Line, Tumor | 5 | 2022 | 16689 | 0.180 |
Why?
|
Diketopiperazines | 1 | 2019 | 20 | 0.180 |
Why?
|
Indole Alkaloids | 1 | 2019 | 24 | 0.180 |
Why?
|
DNA Glycosylases | 1 | 2020 | 128 | 0.170 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2022 | 3597 | 0.170 |
Why?
|
Prenylation | 1 | 2019 | 37 | 0.170 |
Why?
|
Mutation | 9 | 2020 | 29786 | 0.170 |
Why?
|
Research Subjects | 1 | 2021 | 239 | 0.170 |
Why?
|
Government | 1 | 2020 | 165 | 0.170 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2022 | 2016 | 0.170 |
Why?
|
Receptor, Notch1 | 1 | 2022 | 502 | 0.170 |
Why?
|
Standard of Care | 1 | 2023 | 564 | 0.170 |
Why?
|
Adrenal Glands | 1 | 2021 | 546 | 0.170 |
Why?
|
Prospective Studies | 11 | 2023 | 53288 | 0.170 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2021 | 2649 | 0.170 |
Why?
|
Nomograms | 1 | 2020 | 228 | 0.170 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2019 | 37 | 0.170 |
Why?
|
Risk Factors | 12 | 2020 | 72290 | 0.170 |
Why?
|
Cell Cycle Proteins | 3 | 2022 | 3462 | 0.170 |
Why?
|
Genomic Structural Variation | 1 | 2018 | 64 | 0.160 |
Why?
|
Germ-Line Mutation | 4 | 2020 | 1788 | 0.160 |
Why?
|
Calcitonin | 1 | 2019 | 336 | 0.160 |
Why?
|
Ribonuclease III | 1 | 2020 | 275 | 0.160 |
Why?
|
Disease Progression | 7 | 2023 | 13284 | 0.160 |
Why?
|
Endothelial Cells | 1 | 2011 | 3479 | 0.160 |
Why?
|
Nephroma, Mesoblastic | 1 | 2017 | 25 | 0.160 |
Why?
|
Healthcare Disparities | 1 | 2013 | 3158 | 0.160 |
Why?
|
Carbazoles | 1 | 2019 | 226 | 0.160 |
Why?
|
Legislation, Drug | 1 | 2020 | 206 | 0.160 |
Why?
|
Academies and Institutes | 1 | 2020 | 317 | 0.150 |
Why?
|
Stem Cells | 1 | 2011 | 3567 | 0.150 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 402 | 0.150 |
Why?
|
Jumonji Domain-Containing Histone Demethylases | 1 | 2018 | 182 | 0.150 |
Why?
|
Research Design | 3 | 2023 | 5987 | 0.150 |
Why?
|
Blood Pressure | 1 | 2013 | 8554 | 0.150 |
Why?
|
DEAD-box RNA Helicases | 1 | 2020 | 375 | 0.150 |
Why?
|
Administration, Oral | 4 | 2020 | 3913 | 0.150 |
Why?
|
Gene Expression Profiling | 3 | 2019 | 9438 | 0.150 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2017 | 136 | 0.150 |
Why?
|
Lung Neoplasms | 4 | 2023 | 13102 | 0.150 |
Why?
|
Retreatment | 1 | 2018 | 610 | 0.140 |
Why?
|
Microtubule-Associated Proteins | 2 | 2022 | 1086 | 0.140 |
Why?
|
Genetic Heterogeneity | 1 | 2020 | 733 | 0.140 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2020 | 780 | 0.140 |
Why?
|
Survivors | 3 | 2016 | 2291 | 0.140 |
Why?
|
Leukemia | 2 | 2016 | 1511 | 0.140 |
Why?
|
Signal Transduction | 2 | 2021 | 23403 | 0.140 |
Why?
|
Health Services Accessibility | 1 | 2013 | 5137 | 0.140 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2017 | 692 | 0.140 |
Why?
|
Leukemia, Myeloid | 1 | 2019 | 707 | 0.140 |
Why?
|
Pediatrics | 6 | 2021 | 3475 | 0.140 |
Why?
|
Tongue Neoplasms | 1 | 2017 | 180 | 0.140 |
Why?
|
Risk | 3 | 2019 | 9687 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2007 | 3508 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 1434 | 0.130 |
Why?
|
Tablets | 1 | 2016 | 145 | 0.130 |
Why?
|
Blood Sedimentation | 1 | 2016 | 231 | 0.130 |
Why?
|
Models, Biological | 3 | 2021 | 9583 | 0.130 |
Why?
|
Glucuronosyltransferase | 1 | 2016 | 128 | 0.130 |
Why?
|
Recurrence | 6 | 2016 | 8340 | 0.130 |
Why?
|
Drug Discovery | 2 | 2020 | 1058 | 0.130 |
Why?
|
Histone Deacetylases | 2 | 2018 | 728 | 0.130 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 973 | 0.130 |
Why?
|
Syndrome | 1 | 2021 | 3251 | 0.130 |
Why?
|
Pelvic Bones | 1 | 2017 | 265 | 0.130 |
Why?
|
Proto-Oncogene Proteins | 3 | 2023 | 4554 | 0.130 |
Why?
|
Tumor Burden | 4 | 2019 | 1915 | 0.130 |
Why?
|
Rhabdoid Tumor | 1 | 2017 | 212 | 0.130 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 602 | 0.120 |
Why?
|
Lymphatic Metastasis | 2 | 2013 | 2924 | 0.120 |
Why?
|
Dose-Response Relationship, Radiation | 4 | 2020 | 876 | 0.120 |
Why?
|
Acetylation | 2 | 2015 | 1085 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15519 | 0.120 |
Why?
|
Antibodies, Bispecific | 1 | 2016 | 164 | 0.120 |
Why?
|
Transplantation, Autologous | 4 | 2021 | 2124 | 0.120 |
Why?
|
Pyridazines | 1 | 2015 | 202 | 0.120 |
Why?
|
Mitosis | 1 | 2019 | 1208 | 0.120 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1364 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2017 | 538 | 0.120 |
Why?
|
Purines | 1 | 2017 | 594 | 0.120 |
Why?
|
Receptor, IGF Type 1 | 1 | 2016 | 390 | 0.110 |
Why?
|
Paraffin Embedding | 1 | 2014 | 299 | 0.110 |
Why?
|
Aminopyridines | 1 | 2017 | 542 | 0.110 |
Why?
|
Genetic Engineering | 1 | 2019 | 951 | 0.110 |
Why?
|
Cisplatin | 3 | 2022 | 1662 | 0.110 |
Why?
|
Incidence | 6 | 2020 | 20947 | 0.110 |
Why?
|
Killer Cells, Natural | 1 | 2002 | 2133 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 860 | 0.110 |
Why?
|
Nifedipine | 1 | 2013 | 226 | 0.110 |
Why?
|
Growth Plate | 1 | 2014 | 274 | 0.110 |
Why?
|
International Cooperation | 2 | 2021 | 1420 | 0.110 |
Why?
|
Immunologic Factors | 1 | 2022 | 1580 | 0.110 |
Why?
|
Serine Endopeptidases | 1 | 2017 | 1072 | 0.100 |
Why?
|
Powders | 1 | 2011 | 80 | 0.100 |
Why?
|
Extremities | 1 | 2017 | 865 | 0.100 |
Why?
|
Pyrrolidinones | 1 | 2012 | 117 | 0.100 |
Why?
|
Models, Animal | 1 | 2018 | 2171 | 0.100 |
Why?
|
Middle Aged | 18 | 2023 | 213383 | 0.100 |
Why?
|
Multivariate Analysis | 3 | 2014 | 12245 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9959 | 0.100 |
Why?
|
Genome | 1 | 2020 | 1808 | 0.100 |
Why?
|
Piperidines | 1 | 2019 | 1602 | 0.100 |
Why?
|
Dexmedetomidine | 1 | 2015 | 315 | 0.100 |
Why?
|
Radiosurgery | 1 | 2020 | 1329 | 0.100 |
Why?
|
Melanoma | 2 | 2019 | 5510 | 0.100 |
Why?
|
Age Distribution | 1 | 2017 | 2902 | 0.100 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2703 | 0.090 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2012 | 252 | 0.090 |
Why?
|
Telangiectasis | 1 | 2010 | 76 | 0.090 |
Why?
|
Aged, 80 and over | 7 | 2023 | 57776 | 0.090 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2011 | 140 | 0.090 |
Why?
|
Forecasting | 1 | 2019 | 2951 | 0.090 |
Why?
|
Antigens, CD | 2 | 2011 | 4026 | 0.090 |
Why?
|
Risk Assessment | 4 | 2020 | 23338 | 0.090 |
Why?
|
NF-kappa B | 1 | 2018 | 2499 | 0.090 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2010 | 114 | 0.090 |
Why?
|
Proteinuria | 1 | 2012 | 658 | 0.080 |
Why?
|
Dactinomycin | 1 | 2009 | 318 | 0.080 |
Why?
|
Biopsy | 1 | 2020 | 6756 | 0.080 |
Why?
|
Vasodilator Agents | 1 | 2013 | 977 | 0.080 |
Why?
|
Chronic Disease | 1 | 2023 | 9146 | 0.080 |
Why?
|
Aged | 12 | 2023 | 163280 | 0.080 |
Why?
|
Fibromatosis, Aggressive | 1 | 2009 | 118 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 4 | 2021 | 35421 | 0.080 |
Why?
|
DNA Damage | 1 | 2018 | 2432 | 0.080 |
Why?
|
Gene Expression | 2 | 2018 | 7799 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2012 | 578 | 0.080 |
Why?
|
Statistics, Nonparametric | 3 | 2020 | 2886 | 0.080 |
Why?
|
Pilot Projects | 2 | 2020 | 8324 | 0.080 |
Why?
|
Stem Cell Transplantation | 2 | 2016 | 1620 | 0.080 |
Why?
|
Lipoma | 1 | 2010 | 334 | 0.080 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3647 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 380 | 0.080 |
Why?
|
Hypnotics and Sedatives | 1 | 2015 | 1162 | 0.080 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2014 | 981 | 0.080 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 4 | 2022 | 20129 | 0.070 |
Why?
|
Quinolines | 1 | 2012 | 732 | 0.070 |
Why?
|
Liposarcoma | 1 | 2010 | 333 | 0.070 |
Why?
|
Mass Spectrometry | 1 | 2014 | 2203 | 0.070 |
Why?
|
Escherichia coli | 1 | 2019 | 4217 | 0.070 |
Why?
|
Linear Models | 1 | 2017 | 5952 | 0.070 |
Why?
|
Busulfan | 2 | 2021 | 263 | 0.070 |
Why?
|
Immunotherapy | 1 | 2022 | 4445 | 0.070 |
Why?
|
Boronic Acids | 1 | 2010 | 965 | 0.070 |
Why?
|
Immunohistochemistry | 3 | 2015 | 11366 | 0.070 |
Why?
|
Drug Utilization | 1 | 2012 | 1183 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 25043 | 0.070 |
Why?
|
Melphalan | 2 | 2021 | 431 | 0.070 |
Why?
|
Models, Statistical | 1 | 2020 | 5102 | 0.060 |
Why?
|
Upper Extremity | 1 | 2010 | 648 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2013 | 3479 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2017 | 3523 | 0.060 |
Why?
|
Carcinoma, Small Cell | 1 | 2007 | 420 | 0.060 |
Why?
|
Acute Disease | 2 | 2013 | 7149 | 0.060 |
Why?
|
Asparaginase | 2 | 2020 | 236 | 0.060 |
Why?
|
Genotype | 2 | 2016 | 12951 | 0.060 |
Why?
|
Anti-Infective Agents | 1 | 2012 | 972 | 0.060 |
Why?
|
Pyrazines | 1 | 2010 | 1230 | 0.060 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6234 | 0.060 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2007 | 648 | 0.060 |
Why?
|
Receptors, Progesterone | 1 | 2008 | 1097 | 0.060 |
Why?
|
Cell Adhesion Molecules | 1 | 2010 | 1602 | 0.060 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2020 | 1375 | 0.060 |
Why?
|
Mice, Nude | 3 | 2018 | 3689 | 0.060 |
Why?
|
Cyclin B | 1 | 2023 | 108 | 0.050 |
Why?
|
Hospitals, Pediatric | 1 | 2012 | 1775 | 0.050 |
Why?
|
Phenotype | 2 | 2020 | 16365 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2011 | 21746 | 0.050 |
Why?
|
Plasma Cell Granuloma, Pulmonary | 1 | 2021 | 13 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 4034 | 0.050 |
Why?
|
Hearing Loss | 1 | 2009 | 765 | 0.050 |
Why?
|
Animals | 8 | 2020 | 168757 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2012 | 2759 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 2016 | 2274 | 0.050 |
Why?
|
European Union | 1 | 2021 | 158 | 0.050 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 26 | 0.050 |
Why?
|
Sacrum | 1 | 2022 | 288 | 0.050 |
Why?
|
Hospital Mortality | 1 | 2014 | 5317 | 0.050 |
Why?
|
Clinical Protocols | 2 | 2016 | 1462 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 4 | 2021 | 17446 | 0.050 |
Why?
|
Receptors, Estrogen | 1 | 2008 | 2187 | 0.050 |
Why?
|
Nucleotides | 1 | 2023 | 464 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2017 | 7880 | 0.050 |
Why?
|
Tanzania | 2 | 2015 | 1346 | 0.050 |
Why?
|
Bone and Bones | 1 | 2011 | 2575 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2018 | 2012 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2020 | 152 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15076 | 0.040 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2020 | 115 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2020 | 146 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7785 | 0.040 |
Why?
|
Therapies, Investigational | 1 | 2020 | 112 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3557 | 0.040 |
Why?
|
Repressor Proteins | 2 | 2023 | 3023 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2012 | 5021 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 903 | 0.040 |
Why?
|
Dexamethasone | 2 | 2020 | 1951 | 0.040 |
Why?
|
Radiation Dosage | 2 | 2020 | 1928 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2010 | 1797 | 0.040 |
Why?
|
Arabinonucleosides | 1 | 2017 | 35 | 0.040 |
Why?
|
Radiography | 1 | 2009 | 7023 | 0.040 |
Why?
|
Heart | 1 | 2011 | 4467 | 0.040 |
Why?
|
Drug Labeling | 1 | 2020 | 233 | 0.040 |
Why?
|
Adenine Nucleotides | 1 | 2017 | 121 | 0.040 |
Why?
|
Annual Reports as Topic | 1 | 2017 | 33 | 0.040 |
Why?
|
Isotretinoin | 1 | 2018 | 114 | 0.040 |
Why?
|
Receptor, trkB | 1 | 2018 | 125 | 0.040 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2016 | 2109 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 12072 | 0.040 |
Why?
|
Rare Diseases | 1 | 2021 | 553 | 0.040 |
Why?
|
Oncogenes | 1 | 2022 | 1265 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2017 | 318 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2017 | 367 | 0.030 |
Why?
|
Fatal Outcome | 2 | 2012 | 1850 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2017 | 373 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2004 | 1179 | 0.030 |
Why?
|
Germany | 1 | 2018 | 862 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2020 | 764 | 0.030 |
Why?
|
Benzothiazoles | 1 | 2016 | 248 | 0.030 |
Why?
|
Morpholines | 1 | 2018 | 571 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2971 | 0.030 |
Why?
|
Genetic Testing | 2 | 2017 | 3444 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1182 | 0.030 |
Why?
|
Stomatitis | 1 | 2016 | 269 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1782 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3339 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 1999 | 987 | 0.030 |
Why?
|
Radiation Injuries | 1 | 2020 | 1180 | 0.030 |
Why?
|
Organ Specificity | 1 | 2018 | 2008 | 0.030 |
Why?
|
Blotting, Western | 2 | 2011 | 5179 | 0.030 |
Why?
|
Hypertension | 1 | 2013 | 8480 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2016 | 1590 | 0.030 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 528 | 0.030 |
Why?
|
Metanephrine | 1 | 2012 | 26 | 0.030 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2012 | 41 | 0.030 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2016 | 491 | 0.030 |
Why?
|
Compassionate Use Trials | 1 | 2012 | 46 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2021 | 2107 | 0.030 |
Why?
|
Sarcoma, Clear Cell | 1 | 2012 | 76 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 2959 | 0.030 |
Why?
|
Minnesota | 1 | 2012 | 344 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4751 | 0.020 |
Why?
|
Tumor Stem Cell Assay | 1 | 2011 | 118 | 0.020 |
Why?
|
Treatment Failure | 1 | 2017 | 2618 | 0.020 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2012 | 281 | 0.020 |
Why?
|
Base Sequence | 1 | 2022 | 12797 | 0.020 |
Why?
|
Conscious Sedation | 1 | 2015 | 528 | 0.020 |
Why?
|
Cephalosporins | 1 | 2012 | 204 | 0.020 |
Why?
|
California | 1 | 2015 | 1402 | 0.020 |
Why?
|
Drug Utilization Review | 1 | 2012 | 245 | 0.020 |
Why?
|
Regression Analysis | 1 | 2020 | 6459 | 0.020 |
Why?
|
Protein Kinases | 1 | 2018 | 1640 | 0.020 |
Why?
|
Epigenomics | 1 | 2016 | 903 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 1941 | 0.020 |
Why?
|
Gamma Rays | 1 | 2011 | 320 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2015 | 1254 | 0.020 |
Why?
|
Inappropriate Prescribing | 1 | 2012 | 202 | 0.020 |
Why?
|
Age of Onset | 1 | 2016 | 3271 | 0.020 |
Why?
|
Software | 2 | 2015 | 4443 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2014 | 1677 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2011 | 349 | 0.020 |
Why?
|
Methotrexate | 1 | 2016 | 1727 | 0.020 |
Why?
|
Vancomycin | 1 | 2012 | 501 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2046 | 0.020 |
Why?
|
Luminescent Proteins | 1 | 2011 | 853 | 0.020 |
Why?
|
Mice | 4 | 2018 | 81183 | 0.020 |
Why?
|
Health Policy | 1 | 2020 | 2661 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4803 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2018 | 3768 | 0.020 |
Why?
|
Pregnancy | 1 | 2008 | 29144 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15226 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2010 | 791 | 0.020 |
Why?
|
Myelodysplastic Syndromes | 1 | 2016 | 1352 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12959 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6196 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2012 | 1265 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2011 | 1276 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2007 | 712 | 0.020 |
Why?
|
Family Health | 1 | 2010 | 1282 | 0.020 |
Why?
|
Prescription Drugs | 1 | 2012 | 595 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3743 | 0.020 |
Why?
|
Hematologic Neoplasms | 1 | 2016 | 1832 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2008 | 1100 | 0.020 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5256 | 0.010 |
Why?
|
Contrast Media | 1 | 2017 | 5300 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2011 | 1613 | 0.010 |
Why?
|
Developing Countries | 1 | 2015 | 2815 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6314 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3086 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2382 | 0.010 |
Why?
|
Parents | 1 | 2016 | 3407 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 4042 | 0.010 |
Why?
|
Transcription Factors | 1 | 2022 | 12208 | 0.010 |
Why?
|
Pedigree | 1 | 2010 | 4644 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10638 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2011 | 4204 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 13033 | 0.010 |
Why?
|
Cell Survival | 1 | 2011 | 5882 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10388 | 0.010 |
Why?
|
Carcinoma, Renal Cell | 1 | 2012 | 3143 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2011 | 10481 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9727 | 0.010 |
Why?
|
Quality of Life | 1 | 2012 | 12804 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2017 | 20822 | 0.010 |
Why?
|